We boldly develop novel therapeutics utilizing cellular gene editing and complex cytokines We boldly develop novel therapeutics utilizing cellular gene editing and complex cytokines OUR FOCUS
Brooklyn ImmunoTherapeutics (BTX) is committed to creating a world in which patients and families with high unmet medical needs have access to effective treatments. To achieve this, we are focused on three primary approaches:
- iPSC-derived, iMSC-based therapeutics
- In vivo gene editing products
- IRX-2, a human cell-derived (hd) IL-2 therapeutic
LATEST NEWS
Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021
[ READ MORE ]
Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Monday, September 20, 2021, at 4:30 PM ET
[ READ MORE ]
Brooklyn ImmunoTherapeutics to Participate in Grand Opening of Cambridge-Based mRNA Cleanroom Facility Shared with Factor Bioscience
[ READ MORE ]
Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Thursday, August 19, 2021 at 4:30 PM ET
[ READ MORE ]
LATEST PRESENTATION